Area of research
Obstetrics and Gynecology · Pediatrics, Perinatology and Child Health
Research interest
Research interests include Pregnancy and preeclampsia studies, Maternal and fetal healthcare, Birth, Development, and Health, and Cardiovascular Issues in Pregnancy.
Internal and external validation of a machine learning algorithm to detect preeclampsia-related adverse outcomes in high-risk pregnancies
Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1/placental growth factor test for routine clinical evaluation of hospitalized women with hypertensive disorders of pregnancy
Neonatal cost savings in hypertensive disorders of pregnancy: Economic evaluation of the sFlt-1/PlGF test with real world implementation of biomarkers
Circulating follistatin-like 3 and its association with postpartum cardiovascular dysfunction and severe maternal morbidity
Real-world evidence for utility of serum angiogenic and antiangiogenic biomarker testing
Real-world evidence for the utility of serum soluble fms–like tyrosine kinase 1/placental growth factor testing
Response to the Letter to the Editor: “Signs or symptoms of suspected preeclampsia – A retrospective National database study of prevalence, costs, and outcomes”
Elevating the real-world utility of sFlt-1/PlGF testing in hypertensive disorders of pregnancy: strengths and considerations
Placental senescence pathophysiology is shared between peripartum cardiomyopathy and preeclampsia in mouse and human
Placental senescence pathophysiology is shared between peripartum cardiomyopathy and preeclampsia in mouse and human.
Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1/placental growth factor test for routine clinical evaluation of hospitalized women with hypertensive disorders of pregnancy
Plasma soluble fms-like tyrosine kinase 1 to placental growth factor ratio of 11.5 multiples of median predicts preeclampsia with severe features within 2 weeks of testing
Systematic treatment and management of postpartum hypertension using remote patient monitoring
sFlt1/PlGF among patients with suspected preeclampsia when considering hypertensive status
Patient perceptions of remote patient monitoring program for hypertensive disorders of pregnancy.
Clinical utility of angiogenic biomarkers
The additive role of angiogenic markers for women with confirmed preeclampsia
Bioflavonoid luteolin prevents <scp>sFlt</scp> ‐1 release via <scp>HIF</scp> ‐1α inhibition in cultured human placenta
Luteolin prevents TNF-α-induced NF-κB activation and ROS production in cultured human placental explants and endothelial cells
Bioflavonoid luteolin prevents sFlt-1 release via HIF-1α inhibition in cultured human placenta.
Patient and provider perception of home blood pressure monitoring kits
Angiogenic Biomarkers for Preeclampsia in Clinical Setting: A New Era.
A Comparison of Obstetric Interventions and Outcomes Between Black and White Patients at an Urban Tertiary Medical Center.
Racial differences in healthcare utilization among patients with suspected or diagnosed preeclampsia: A retrospective cohort study
Reducing the Risk of Term Preeclampsia by Risk-Stratified Timing of Birth: Time to Deliver.
Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy
Elimination of racial disparities in postpartum hypertension follow-up after incorporation of telehealth into a quality bundle
Racial Disparities in Diagnosis, Management, and Outcomes in Preeclampsia
The additive role of angiogenic markers for women with confirmed preeclampsia
Angiogenic Biomarkers for Risk Stratification in Women with Preeclampsia